In:
Therapeutic Advances in Gastroenterology, SAGE Publications, Vol. 5, No. 1 ( 2012-01), p. 31-36
Abstract:
A proportion of patients with celiac disease have a poor response to a gluten-free diet, which may be due to small-intestinal bacterial overgrowth (SIBO). Treatment with rifaximin is often used in the clinical setting, but there is limited literature to support this practice. In addition, challenges in the diagnosis of SIBO confound response interpretation. Our recent placebo-controlled trial did not demonstrate any improvement in gastrointestinal symptoms after treatment with rifaximin and casts doubt on the utility of lactulose–hydrogen breath testing for SIBO in this population.
Type of Medium:
Online Resource
ISSN:
1756-2848
,
1756-2848
DOI:
10.1177/1756283X11422264
Language:
English
Publisher:
SAGE Publications
Publication Date:
2012
detail.hit.zdb_id:
2440710-0